# Immunophenotype of PBMC to Early Predict Response to Immunotherapy in Hepatocellular Carcinoma

> **NCT06777628** · — · RECRUITING · sponsor: **IRCCS Azienda Ospedaliero-Universitaria di Bologna** · enrollment: 100 (estimated)

## Conditions studied

- Liver Cancer, Adult

## Interventions

- **DRUG:** Immunochemotherapy combined with antiangiogenic

## Key facts

- **NCT ID:** NCT06777628
- **Lead sponsor:** IRCCS Azienda Ospedaliero-Universitaria di Bologna
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-15
- **Primary completion:** 2026-10-15
- **Final completion:** 2028-10-15
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2025-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06777628

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06777628, "Immunophenotype of PBMC to Early Predict Response to Immunotherapy in Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06777628. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*